Not Disclosed (Clinical Asset)
Oncology
Key Facts
About Oxford BioTherapeutics
Oxford BioTherapeutics is a clinical-stage oncology biotech leveraging its unique OGAP®-Verify proteomic discovery platform to identify novel membrane protein targets and develop first-in-class targeted therapies. The company has built a diversified pipeline with three clinical-stage assets and nine partnered programs, supported by six key industry partnerships. With over 50 employees and R&D sites in the UK and US, OBT employs a capital-efficient, partnership-centric business model to advance its innovative antibody-based therapeutics across multiple modalities.
View full company profileAbout Oxford BioTherapeutics
Oxford BioTherapeutics is a clinical-stage oncology biotech leveraging its unique OGAP®-Verify proteomic discovery platform to identify novel membrane protein targets and develop first-in-class targeted therapies. The company has built a diversified pipeline with three clinical-stage assets and nine partnered programs, supported by six key industry partnerships. With over 50 employees and R&D sites in the UK and US, OBT employs a capital-efficient, partnership-centric business model to advance its innovative antibody-based therapeutics across multiple modalities.
View full company profileAbout Oxford BioTherapeutics
Oxford BioTherapeutics is a clinical-stage oncology biotech leveraging its unique OGAP®-Verify proteomic discovery platform to identify novel membrane protein targets and develop first-in-class targeted therapies. The company has built a diversified pipeline with three clinical-stage assets and nine partnered programs, supported by six key industry partnerships. With over 50 employees and R&D sites in the UK and US, OBT employs a capital-efficient, partnership-centric business model to advance its innovative antibody-based therapeutics across multiple modalities.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |